NEW YORK (360Dx) – Owlstone Medical announced today an investment by Aviva Ventures, the venture capital arm of insurance company Aviva, which that it will use to drive commercialization of its breath biopsy platform and test adoption.

The investment takes Owlstone Medical's total funding to $23.5 million since it was spun off from Owlstone Inc. in 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.